A Step-by-Step Guide to Understanding the FDA’s New Rules on Compounded Obesity Drugs and Leadership Changes

Introduction

If you’ve been following the buzz around weight loss and diabetes medications, you’ve likely heard about the U.S. Food and Drug Administration’s recent decisions. The agency proposed removing semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (used in Mounjaro and Zepbound) from the list of substances that large compounding facilities can use to make bulk versions. This move is a win for drugmakers Novo Nordisk and Eli Lilly, but it reshapes options for consumers. Additionally, the FDA installed Dr. Katherine Szarama as the acting director of the Center for Biologics Evaluation and Research (CBER), replacing the controversial Vinay Prasad. This guide walks you through what happened, why it matters, and what to do next—step by step.

What You Need

• Basic understanding of prescription drug compounding – Compounding means combining, mixing, or altering ingredients to create a customized medication. Large compounding facilities (outsourcing facilities) can produce batches of drugs without individual prescriptions under certain FDA rules.
• Knowledge of the drugs involved – Semaglutide (Novo Nordisk’s Wegovy, Ozempic) and tirzepatide (Eli Lilly’s Mounjaro, Zepbound) are GLP-1 receptor agonists used for weight loss and diabetes.
• Familiarity with FDA regulatory pathways – Specifically, the “clinical need” standard for inclusion on the 503B bulk drug substances list.
• Access to reliable sources – For deeper details, you may want STAT+ or the FDA’s official statements.
• Time to read 10-15 minutes – This guide is concise but packed with context.

Step-by-Step Guide

1. Step 1: Grasp the FDA’s Proposal on Obstetrics and Diabetes Drug Compounding

   The FDA recently proposed to exclude semaglutide and tirzepatide from the list of bulk drug substances that outsourcing facilities can compound and distribute in large quantities. Why? The agency determined there is no “clinical need” to allow such compounding. In simpler terms, the drugs are already widely available as FDA-approved brand-name products, so making compounded copies at scale isn’t necessary to meet patient demand. This decision came after growing controversy over the role of large compounders in supplying cheaper alternatives to brand-name obesity treatments. For patients and prescribers, this means it will become harder to access compounded versions of these popular drugs—a clear win for Novo Nordisk and Eli Lilly.

2. Step 2: Understand the Impact on Consumers and Drugmakers

   This proposal is a victory for Novo Nordisk and Eli Lilly, but it reworks choices for consumers. Previously, many patients turned to compounded semaglutide and tirzepatide due to lower costs or shortages of the brand-name injections. If the rule is finalized, large compounding facilities (503B facilities) will no longer be legally allowed to manufacture these bulk copies. Patients may need to rely on brand-name prescriptions or find alternative treatments. However, small-scale, patient-specific compounding (under 503A) is still permitted, so compounded versions aren’t entirely gone—they just become harder to get in large batches. The FDA explained that these compounders no longer meet the legal requirements to market their products, citing the discontinuation of shortage status for the original drugs.

3. Step 3: Recognize the Controversy Behind Compounding Decisions

   Compounding has been a lifeline for many patients when brand-name drugs are in shortage or unaffordable. The obesity drug market exploded in 2023-2025, leading to soaring demand and periodic shortages. This opened the door for compounders to fill the gap, often with injectable versions that may differ in quality or dosing. The FDA’s proposal signals a tightening of the rules. Critics argue this limits patient access, while supporters say it protects safety and intellectual property. Understanding this tension is key to following the debate. For more detail, you can read the full STAT+ article referenced in the original news.

   

4. Step 4: Learn About the New Acting Director of CBER

   In parallel, the FDA named Dr. Katherine Szarama as the acting director of the Center for Biologics Evaluation and Research (CBER). CBER oversees vaccines, gene therapies, and the blood supply. She replaces Vinay Prasad, who left the agency on Thursday after a tumultuous tenure marked by controversial decisions on rare disease drugs and vaccines. Dr. Szarama joined the FDA at the end of last year as Prasad’s deputy. It is not clear if she will serve permanently. Government and industry sources previously indicated that Dr. Houman Hemmati—an ophthalmologist, biopharma executive, and frequent Fox News contributor—was a top candidate for the role. This leadership change is significant because CBER’s direction affects the approval and regulation of cutting-edge therapies.

5. Step 5: Assess Future Implications for Patients and Providers

   Looking ahead, patients and healthcare providers should monitor the FDA’s final ruling on the compounding list—expected within months. If the exclusion stands, major wholesale clubs and online pharmacies will likely stop offering compounded semaglutide or tirzepatide. However, smaller compounding pharmacies (503A) can still create custom doses for individual patients with a prescription. Additionally, the leadership at CBER may influence how quickly new weight loss drugs or biologics are approved. For now, the best strategy is to discuss options with your doctor: brand-name drugs are more regulated, but may be costlier. Patient assistance programs or insurance coverage might help.

Tips for Staying Informed

• Follow FDA announcements – The official dockets on the bulk substances list will be open for public comment. Check FDA.gov regularly.
• Consult a healthcare professional – Before seeking compounded medications, ask your prescriber about safety, efficacy, and alternatives.
• Be cautious of unregulated sources – Compounded drugs are not FDA-approved; quality can vary. Only use pharmacies that are state-licensed and 503B-registered if applicable.
• Keep an eye on CBER leadership – The appointment of a permanent director will shape vaccine and gene therapy policies. Watch for updates via STAT News or industry outlets.
• Understand your rights – If you rely on a compounded version, talk to your pharmacist about transition plans if the prohibition goes into effect.